Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December

Company Overview - Echo IQ is an AI and Medical Technology company based in Sydney, Australia, focused on improving decision-making in Cardiology through AI-driven technology and proprietary software [4]. Recent Developments - The CEO of Echo IQ, Dustin Haines, will present at the Life Sciences Virtual Investor Forum on December 11, 2025 [1][2]. - EchoSolv AS, an FDA-approved solution, has seen significant commercial traction in the U.S., with a 153% increase in echocardiograms processed from July to September 2025 [6]. - There was a 58% uplift in echocardiogram processing from September to October 2025 [6]. - The company entered into a reseller agreement with SARC MedIQ, expanding the use of EchoSolv AS through a network of hospitals and cardiology practices in the U.S. [6]. Clinical Results - Preliminary top-line clinical results from the EchoSolv HF validation study show a sensitivity of 99.5% and specificity of 91.0% in identifying patients with and without Heart Failure, respectively [6]. - The company plans to submit for FDA clearance of EchoSolv HF via the 510(k) regulatory pathway in December 2025, anticipating clearance in the first half of calendar year 2026 [6]. Market Context - Heart failure and aortic stenosis are significant health challenges in the U.S., driving over US$65 billion in annual healthcare costs [6].